Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

Full description

Bibliographic Details
Main Authors: Michael Riste, Julia L. Marshall, Iman Satti, Stephanie A. Harris, Morven Wilkie, Raquel Lopez Ramon, Danny Wright, Rachel E. Wittenberg, Samantha Vermaak, Rebecca Powell Doherty, Alison Lawrie, Christopher P. Conlon, Catherine Cosgrove, Fergus Gleeson, Marc Lipman, Paul Moss, Felicity Perrin, Martin Dedicoat, Henry Bettinson, Helen McShane
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Vaccines
Subjects:
aerosol vaccine
MVA85A
mycobacteria
latent TB infection
Online Access:https://www.mdpi.com/2076-393X/9/4/396

Internet

https://www.mdpi.com/2076-393X/9/4/396

Similar Items